London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb ...

DHA Omega-3 Supplements from Canola Health Canada has Approved Nutriterra DHA Canola as an ingredient in dietary supplements ...

TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.